Concepts in Advanced Renal Carcinoma

Seminars in Oncology Nursing

Volumn 28, Issue 3, 2012, Pages 170-179

  Esper, Peg ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Kidney cancer; Targeted therapy

Indexed keywords

ARTICLE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METHODOLOGY; NURSING; ONCOLOGY NURSING;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; ONCOLOGIC NURSING;

EID: 84864343329     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.05.006     Document Type: Article

References (46)

1. Siegel R., Naishadham M.A., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 2012(62):10-29.
2. Cairns P. Renal cell carcinoma. Cancer Biomark 2011, 9:461-473.
3. Koul H., Huh J.S., Rove K.O., et al. Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res 2011, 1:240-254.
4. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
5. Curti B.D. Renal cell carcinoma. JAMA 2004, 292:97-100.
6. Haas N.B., Uzzo R.G. Targeted therapies for kidney cancer in urologic practice. Urol Oncol 2007, 25:420-432.
7. Edge S.B. AJCC cancer staging manual 2010, American Joint Committee on Cancer, Springer, New York. Ed 7.
8. Sadeghi S., Albiges L., Wood L.S., et al. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and clinical outcome. Cancer 2011, 118:3277-3284.
9. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
10. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
11. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463.
12. Leung H.W., Chan A.L. Multikinase inhibitors in metastatic renal cell carcinoma: Indirect comparison meta-analysis. Clin Ther 2011, 33:708-716.
13. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology for kidney cancer. Version 1. 2012. Available at: Accessed November 5, 2011. http://www.NCCN.org.
14. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
15. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group.
16. Gross-Goupil M., Massard C., Ravaud A. Targeted therapies in metastatic renal cell carcinoma: overview of the past year. Curr Urol Rep 2012, 13:16-23.
17. Bex A., Jonasch E., Kirkali Z., et al. Integrating surgery with targeted therapies for renal cell carcinoma: Current evidence and ongoing trials. Eur Urol 2010, 58:819-828.
18. Dutcher J.P., Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011, 28:1530-1533.
19. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127-3132.
20. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141.
21. Dillman R.O., Barth N.M., VanderMolen L.A., et al. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?. Cancer Biother Radiopharm 2011, 26:273-277.
22. Shablak A., Sikand K., Shanks J.H., et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 2011, 34:107-112.
23. Atkins M.B., Choueiri T.K., Cho D., et al. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 2009, 115:2327-2333.
24. Coppin C., Kollmannsberger C., Le L., et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011, 108:1556-1563.
25. Molina A.M., Motzer R.J. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011, 16(suppl 2):45-50.
26. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
27. Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007, 13:1098-1106.
28. Hudes G.R., Carducci M.A., Choueiri T.K., et al. NCCN task force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011, 9(suppl 1):S1-29.
29. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010, 10:505-514.
30. Esper P., Gale D., Muehlbauer P. What kind of rash is it?: Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs 2007, 11:659-666.
31. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182:396-403.
32. Rosenbaum S.E., Wu S., Newman M.A., et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008, 16:557-566.
33. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011, 16(suppl 2):32-44.
34. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
35. Billemont B., Medioni J., Taillade L., et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008, 99:1380-1382.
36. Porta C., Tortora G., Linassier C., et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: An expert agreement. Med Oncol 2011, [Epub ahead of print].
37. Hutson T.E., Bukowski R.M., Cowey C.L., et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2011, 77:48-62.
38. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
39. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34. discussion 34.
40. Gerullis H., Bergmann L., Maute L., et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010, 27:373-378.
41. Forauer A.R., Kent E., Cwikiel W., et al. Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. Acta Oncol 2007, 46:1012-1018.
42. Gore M.E., Hariharan S., Porta C., et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011, 117:501-509.
43. Wood S.L., Brown J.E. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 2012, 38:284-291.
44. Lipton A., Zheng M., Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:962-969.
45. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
46. Cella D. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist 2011, 16(suppl 2):23-31.